FNY Managed Accounts’s TherapeuticsMD TXMD Stock Holding History

FNY Managed Accounts’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-10	Closed	-$2.93K	–	370
2015 Q3	$2.93K	Sell	10 -10	-50%	-$3.56K	0.01%	337
2015 Q2	$7.86K	Buy	+20	New	+$7.06K	0.01%	341
2014 Q1	–	Sell	-10	Closed	-$3K	–	182
2013 Q4	$3K	Buy	+10	New	+$2.19K	﹤0.01%	142

Other funds holding TXMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

FNY Managed Accounts's TXMD Position: Q4 2015 in Review

FNY Managed Accounts sold out of TherapeuticsMD (TXMD) in Q4 2015, closing a stake of 10 shares — an estimated $2.93K sold.

FNY Managed Accounts first reported a position in TXMD in Q4 2013 and held it in 3 quarters. The position peaked at $7.86K in Q2 2015. 123 funds tracked by Wall St. Rank hold TXMD as of Q4 2015.

FNY Managed Accounts reported no remaining TherapeuticsMD position as of Q4 2015 after selling out during the quarter.
FNY Managed Accounts sold 10 TherapeuticsMD shares in Q4 2015, an estimated $2.93K.
FNY Managed Accounts first reported a position in TherapeuticsMD in Q4 2013 and held it in 3 quarters.
FNY Managed Accounts's TherapeuticsMD position peaked at $7.86K in Q2 2015.
123 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2015.

Based on FNY Managed Accounts's 13F filing for Q4 2015, filed 25 Jan 2016.